About selumetinib
MEK inhibitor
Used for
- Treatment of symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1.
Usual adult dose
Not established for this pediatric indication.
Usual dose in children
25 mg/m² by mouth twice daily, approximately 12 hours apart; dosing is based on body surface area.
Common side effects
- Vomiting, diarrhea, nausea, or abdominal pain
- Rash, dry skin, or acne
- Muscle pain or weakness
- Reduced heart pumping function or eye problems
Important warnings
- Can reduce heart function; monitoring is required.
- May cause serious eye problems, including retinal detachment.
- Can cause muscle injury and elevated creatine kinase.
- Avoid grapefruit and strong CYP3A4 inhibitors or inducers.
Pregnancy
May harm an unborn baby. Pregnancy testing and effective contraception are recommended during treatment and for one week afterward.
Breastfeeding
Do not breastfeed during treatment and for one week after the last dose.
Interactions
- Strong or moderate CYP3A4 inhibitors can increase selumetinib exposure.
- Strong or moderate CYP3A4 inducers can reduce selumetinib exposure.
- Grapefruit may increase exposure.
- May increase exposure to sensitive CYP2C19 or CYP3A4 substrates.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.